PuMP: Oncolytic HSV1 MVR-C5252 in Patients with rHGG (Recurrent Glioma) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find out how safe and effective an experimental drug called MVR-C5252 (the study drug) is for people with advanced brain cancer.
What is the Condition Being Studied?
Malignant Glioma
Who Can Participate in the Study?
Adults ages 18+ who are diagnosed with recurrent high-grade glioma.
For more information about this study, please call 919-668-3726.
Age Group
Adults
What is Involved?
If you join the study, you will:
- Have a physical and neurological exam and other tests
- Have magnetic resonance imaging (MRI) of the brain
- Have blood draws
- Have brain tumor biopsy and testing of tumor sample
- Have a catheter (small flexible tube) placed in and around the tumor with the other end of the catheter extending slightly outside of the head
- Get the study drug infused through an external pump and the implanted catheter
Study Details
Full Title
The PuMP Trial: A Multistage Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252 in Patients with Recurrent High-Grade Glioma
Principal Investigator
Medical Oncologist
Protocol Number
IRB:
PRO00112883
NCT:
NCT06126744
Phase
Phase
I
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Call 919-668-3726